During a meal, two incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released from the small intestine into the vasculature and augment glucose-induced insulin secretion from the islet β-cells . It has been estimated that 50-60% of the total insulin secreted during a meal results from the incretin response, mainly the combined effects of GIP and GLP-1 . Previous studies have shown both GIP and GLP-1 stimulate β-cell proliferation, differentiation, and prevent apoptosis [3-6]. GLP-1 also has some actions such as inhibition of glucagon secretion and food intake, glucose homeostasis and slowing the gastric emptying [7-9]. However, GLP-1 has a short half-life of 1-2 min following secretion in response to the nutrients ingestion because of its inactivation by dipeptidyl peptidase-IV (DPP-IV) , resulting in loss of insulinotropic activities.
DPP-IV (CD26; E.C. 22.214.171.124) is a 110-kDa plasma membrane glycoprotein ectopeptidase that belongs to the prolyl oligopeptidase family . It acts as a cleaving enzyme with the specificity for removing X-Pro or X-Ala dipeptides from the N terminus of polypeptides and proteins. It has a strong preference for Pro > Ala > Ser as the penultimate amino acid residue [10-12]. This enzyme is also capable of cleavage of N-terminal dipeptides with hydroxyproline (Hyp), dehydroproline, Gly, Val, Thr or Leu [10-14]. GLP-1 has Ala as the N-terminal penultimate amino acid residue, and therefore it is the substrate of DPP-IV. This finding that over 95% of the degradation of GLP-1 is attributed to the action of DPP-IV led to an elevated interest in inhibition of this enzyme for the treatment of type 2 diabetes . Some previous studies have shown that specific DPP-IV inhibition increased the half-life of total circulating GLP-1, decreased plasma glucose, and improved impaired glucose tolerance in animal and human experiments [16-18].
There are several chemical compounds used
Proteins are well known as precursors of bioactive peptides. In recent years, peptides have been identified to possess physiological functions, such as immunomodulatory , antimicrobial , antihypertensive , anticancer , antioxidative  and cholesterol-lowering activities . These bioactive peptides are mostly derived from milk, wheat, soybean, egg and fish proteins by enzymatic hydrolysis or fermentation . Food protein hydrolysates are well-used and natural food ingredients, and therefore they are believed to be safe for consumers when they are served as functional foods. Some studies have reported that bioactive peptides possessed DPP-IV inhibitory activity. Diprotins A and B, isolated from culture filtrates of
It is well-known that the dominant amino acid in gelatin is Gly, while the imino acids (Pro and Hyp) come second in abundance . The amino acid composition of gelatin is characterized by a repeating sequence of Gly-X-Y triplets, where X is mostly Pro and Y is mostly Hyp. Inside gelatin molecule, Gly constitutes approximately 27% of the total amino acid pool . The total amount of the imino acids is higher in mammalian (20-24%) than in fish (16-20%). In our previous study, we successfully isolated two peptides, Gly-Pro-Ala-Glu and Gly-Pro-Gly-Ala from Atlantic salmon skin gelatin, that showed dose-dependent inhibitory effects on DPP-IV with IC50 values of 49.6 and 41.9 μM, respectively . According to the report of previous studies, DPP-IV inhibitory peptides consisted of at least one Pro and mostly as the penultimate N-terminal residue . Therefore, the aim of this study was to examine the DPP-IV inhibitory activity of peptides derived from porcine skin gelatin, which constitutes higher content of imino acids than skin gelatin of Atlantic salmon, a kind of cold-water fish. This is expected to give insight into the possible utilization of porcine skin as a potential source of DPP-IV inhibitors that may be used in the treatment of type 2 diabetes to lower the risk of side effects.
2. Materials and methods
2.1. Materials and reagents
Porcine skin gelatin (G-2500) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Alcalase® 2.4 L FG (from
2.2. Enzymatic hydrolysis
One gram of the gelatin added with 50 mL ddH2O was incubated at 50°C for 10 min prior to the enzymatic hydrolysis. ALA in liquid form were weighed 10, 30, 50 mg and mixed with 1 mL ddH2O. The hydrolysis reaction was started by the addition of enzymes at various enzyme/substrate ratios (E/S: 1%, 3%, and 5%). The reaction with ALA was conducted at pH 8.0, respectively, and 50°C for up to 6 h. After hydrolysis, the hydrolysates were heated in boiling water for 15 min to inactivate enzymes and then cooled in cold water at room temperature for 20 min. Hydrolysates were adjusted their pH to 7.0 with 1 M NaOH and centrifuged (Du Pont Sorvall Centrifuge RC 5B, Mandel Scientific Co. Ltd, Guelph, ON, Canada) at 12,000
2.3. Measurement of degree of hydrolysis
Immediately prior to termination of hydrolysis, 4 mL of the hydrolysate were mixed with an equal volume of 24% TCA solution and centrifuged at 12200
2.4. Determination of DPP-IV inhibitory activity
DPP-IV activity determination in this study was performed in 96-well microplates measuring the increase in absorbance at 405 nm using Gly-Pro-p-nitroanilide as DPP-IV substrate . The lyophilized hydrolysates were dissolved in 100 mM Tris buffer (pH 8.0) to the concentration of 10 mg/mL and then serially diluted. The hydrolysates (25 μL) were added with 25 μL of 1.59 mM Gly-Pro-p-nitroanilide (in 100 mM Tris buffer, pH 8.0). The mixture was incubated at 37°C °C for 10 min, followed by the addition of 50 μL of DPP-IV (diluted with the same Tris buffer to 0.01 Unit/mL). The reaction mixture was incubated at 37°C for 60 min, and the reaction was stopped by adding 100 μL of 1 M sodium acetate buffer (pH 4.0). The absorbance of the resulting solution was measured at 405 nm with a microplate reader (iEMS reader MF; Labsystems, Helsinki, Finland). Under the conditions of the assay, IC50 values were determined by assaying appropriately diluted samples and plotting the DPP-IV inhibition rate as a function of the hydrolysate concentration.
Hydrolysates were fractionated by ultrafiltration (UF; Model ABL085, Lian Sheng Tech. Co., Taichung, Taiwan) with spiral wound membranes having molecular mass cutoffs of 2.5 and 1 kDa. The fractions were collected as follows: >2.5 kDa, peptides retained without passing through 2.5 kDa membrane; 1-2.5 kDa, peptides permeating through the 2.5 kDa membrane but not the 1 kDa membrane; <1 kDa, peptides permeating through the 1 kDa membrane. All collected fractions were lyophilized and stored in a desiccator until use.
2.6. High Performance Liquid Chromatography (HPLC)
The fractionated hydrolysates by ultrafiltration exhibiting DPP-IV inhibitory activity were further purified using high performance liquid chromatography (Model L-2130 HPLC, Hitachi Ltd., Katsuda, Japan). The lyophilized hydrolysate fraction (100 μg) by gel filtration was dissolved in 1 mL of 0.1% trifluoroacetic acid (TFA) and 90 μL of the mixture, was then injected into a column (ZORBAX Eclipse Plus C18, 4.6 × 250 mm, Agilent Tech. Inc., CA, USA) using a linear gradient of acetonitrile (5 to 15% in 20 min) in 0.1% TFA under a flow rate of 0.7 mL/min. The peptides were detected at 215 nm. Each collected fraction was lyophilized and stored in a desiccator until use.
2.7. Identification of amino acid sequence
An accurate molecular mass and amino acid sequence of the purified peptides was determined using a Q-TOF mass spectrometer (Micromass, Altrincham, UK) coupled with an electrospray (ESI) source. The purified peptides were separately infused into the ESI source after being dissolved in methanol/water (1:1, v/v), and the molecular mass was determined by the doubly charged (M+2H)+2 state in the mass spectrum. Automated Edman sequencing was performed by standard procedures using a 477-A protein sequencer chromatogram (Applied Biosystems, Foster, CA, USA).
2.8. Peptide synthesis
Peptides were prepared by the conventional Fmoc solid-phase synthesis method with an automatic peptide synthesizer (Model CS 136, CS Bio Co. San Carlos, CA, USA), and their purity was verified by analytical RP-HPLC-MS/MS.
2.9. Statistical analysis
Each data represents the mean of three samples was subjected to analysis of variance (ANOVA) followed by Tukey‘s studentized range test, and the significance level of
3. Results and discussion
3.1. Degree of hydrolysis
The DH of porcine skin gelatin hydrolyzed with ALA increased dramatically during the initial 1 h, and then increased gradually thereafter (Fig. 1). Also the highest DH was obtained with the highest E/S ratio. The highest DH (%) for ALA was 16.7% and obtained at the E/S ratio of 5% and 6-h hydrolysis.
3.2. DPP-IV inhibitory activity of hydrolysates
The DPP-IV inhibitory activity of porcine skin gelatin hydrolysates at the concentration of 10 mg/mL was shown in Fig. 2. The gelatin sample without hydrolysis (0 h) showed 9.2% inhibitory rate on DPP-IV. The DPP-IV inhibitory activity of the gelatin hydrolysates increased with E/S ratio and hydrolysis time. The DPP-IV inhibition rates of the 1-h hydrolysates with the E/S ratio of 1, 3 and 5% were 27.2, 44.3 and 48.8%, respectively; while those of 6-h hydrolysates increased to 52.0, 59.7 and 60.0%. The hydrolysates with the E/S ratio of 3% and 5%, and the hydrolysis time of 4 h and 6 h showed the highest DPP-IV inhibition rates between 57.4 to 60.0% among all the samples (
3.3. DPP-IV inhibitory activtiy of hydrolysates fractionated by UF
The DPP-IV inhibitory activity of hydrolysates with the E/S ratio of 3% and 4-h hydrolysis at the concentration of 1 mg/mL fractionated by UF was shown in Fig. 3A. The result showed the UF fractions of 1-2.5 kDa and < 1 kDa had insignificantly different (
3.4. Purification of DPP-IV-inhibitory peptides by HPLC
The elution profile and DPP-IV inhibitory activity of the peptide fractions from the < 1 kDa UF fraction separated by HPLC were shown in Fig. 4A and B. To obtain a sufficient amount of purified peptide, chromatographic separations were performed repeatedly. Five fractions (F-1 to F-5) were obtained upon HPLC separation of the < 1 kDa UF fraction (Fig. 4A), and they were lyophilized and then used to determine their DPP-IV inhibitory activities at the concentration of 100 μg/mL. The result showed that the fraction F-3 had the highest DPP-IV inhibition rate of 64.6% (
3.5. Amino acid sequence of DPP-IV inhibitory peptides
Two peptides were identified in fraction F-3, and their amino acid sequences were Gly-Pro-Hyp (285.3 Da) and Gly-Pro-Ala-Gly (300.4 Da). Patent WO 2006/068480 has reported that 21 peptides which were capable of inhibiting DPP-IV activity showed a hydrophobic character, had a length varying from 3-7 amino acid residues and in particular the presence of Pro residue within the sequence . The Pro residue was located as the first, second, third or fourth N-terminal residue, but mostly as the second N-terminal residue. Besides, the Pro residue was flanked by Leu, Val, Phe, Ala and Gly. In the present study, both peptides comprised Pro as the second N-terminal residue, and the Pro residue was flanked by Ala and Gly. Moreover, the peptides were composed of mostly hydrophobic amino acid residues, such as Ala, Gly and Pro, and one peptide comprised a charged amino acid, Glu, as the C-terminal residue. The present results therefore are consistent with the hypothesis demonstrated in the previous study .
3.6. DPP-IV-inhibitory activity of the synthetic peptides
The DPP-IV inhibitory activity of the two synthetic peptides and Diprotin A at various concentrations was determined (Fig. 5). The IC50 was calculated for each of the peptides. Diprotin A is well-known as the peptide with the greatest DPP-IV inhibitory activity, and its IC50 value was found as 24.7 μM in the present study (Fig. 4C). The IC50 values of the two synthetic peptides, Gly-Pro-Hyp and Gly-Pro-Ala-Gly, were 49.6 and 41.9 μM, respectively (Fig. 4A, B). In the previous study, the IC50 values against DPP-IV of Diprotin A and Diprotin B isolated from culture filtrates of
This study has clearly demonstrated that porcine skin gelatin could be a good protein source to produce DPP-IV inhibitory peptides by hydrolysis with ALA. The two peptides identified in this study may have the potential for the therapy or prevention of type 2 diabetes. Further studies using
The Entero-Insular Axis in Type 2 Diabetes-Incretins as Therapeutic Agents. Experimental and Clinical Endocrinology & Diabetes Creutzfeldt W. 2001 109 288
Gut Hormones and Diabetes Mellitus. Diabetes/Metabolism Research and Reviews Creutzfeldt W. MA Nauck 1992 8 565
Drucker DJ.Enhancing Incretin Action for the Treatment of Type 2 Diabetes. Diabetes Care 2003 26 2929
Glucose-Dependent Insulinotropic Polypeptide Pormotes β-(INS-1) Cell Survival via Cyclic Adenosine Monophosphate-Mediated Caspase-3 Inhibition and Regulation of Ehses J. A. Casilla V. Doty T. Pospisilik J. A. Demuth H. U. Pederson R. A. Glucose 38Mitogen-Activated Protein Kinase. Endocrinology 2003
Glucose-Dependent Insulinotropic Polypeptide is a Growth Factor for β-(INS-1) Cells by Pleiotropic Signaling. Molucular Endocrinology Trümper A. Trümper K. Trusheim H. Arnold R. Göke B. Hörsch D. Glucose 2001 15 1559
Drucker DJ. Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation and Apoptosis.Molecular Endocrinology 2003 17 161
Hormone and Metabolic Research Ahren B. G. L. P. Extra-Islet Effects. 2004 36 842
De León DD, Crutchlow MF, Ham JYN, Stoffers AS.Role of Glucagon-Like Peptide-1 in the Pathogenesis and Treatment of Diabetes Mellitus. The International Journal of Biochemistry & Cell Biology 2006 38 845
Regulatory Peptides Hansotia T. Drucker D. J. G. I. P. G. L. P. as Incretin Hormones. Lessons from. Single Double Incretin. Receptor Knockout. Mice 2005 128 125
European Journal of Biochemistry Mentlein R. Gallwitz B. Schmidt W. E. Dipeptidyl-Peptidase I. V. Hydrolyses Gastric. Inhibitory Polypeptide. Glucagon-Like Peptide. ( 7 3 Amide Peptide Histidine. Methionine is Responsible. for Their. Degradation in. Human Serum. 1993
Advances in Experimental Medicine and Biology De Meester I. Lambeir A. M. Proost P. Scharpé S. Dipeptidyl Peptidase. I. V. Substrates 2003 524 3
Critical Reviews in Clinical Laboratory Science Lambeir A. M. Durinx C. Scharpé S. De Meester I. Dipeptidyl-Peptidase I. V. from . Bench to. Bedside An. Update on. Structural Properties. Functions Clinical . Aspects of. the Enzyme. D. P. P. I. V. 2003 40 209
Regulatory Peptides. Regulatory Peptides Mentlein R. Dipeptidyl-Peptidase I. V. . C. D-26 Role in. the Inactivation. of Regulatory. Peptides 1999 85 9
The Unique Properties of Dipeptidyl Peptidase IV Inhibitors. Current Medicinal Chemistry Augustyns K. Bal G. Thonus G. Belyaev A. Zhang X. M. Bollaert W. 1999 6 311
Regulatory Peptides Mc Intosh C. H. S. Demuth H. U. Pospisilik J. A. Pederson R. Dipeptidyl Peptidase. I. V. Inhibitors How. do They Work. as New Antidiabetic. Agents 2005 128 159
Deacon CF, Hughes TE, Holst JJ. Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig.Diabetes 1998 47 764
Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetes Subjects as Revealed Using a New Assay for the Intact Peptide. The Journal of Clinical Endocrinology & Metabolism Deacon C. F. MA Nauck Meier. J. Hücking K. Holst J. J. 2000 85 3575
The Japanese Journal of Pharmacology Mitani H. Takimoto M. Hughes T. E. Kimura M. Dipeptidyl Peptidase. I. V. Inhibition Improves. Impaired Glucose. Tolerance in. High-Fat-Fed Diet. Rats Study. Using a. Fischer 3. Rat Substrain. Deficient in. Its Enzyme. Activity 2002 88 442
FEBS Letters Reinhold D. Vetterb R. W. Mnich K. Bühling F. Lendeckel U. Born I. Faust J. Neubert . K. Gollnick H. Ansorge S. Dipeptidyl Peptidase. I. V. . D. P. I. V. C. D2 is Involved. in Regulation. of D. N. A. Synthesis in. Human Keratinocytes. F. E. B. 1998 428 100
Immunomodulatory Peptides Obtained by the Enzyme Hydrolysis of Whey Proteins. International Dairy Journal Gauthier S. F. Pouliot Y. Saint-Sauveur D. 2006 16 1315
Bacteriocin-Based Strategies for Food Biopreservation. International Journal of Food Microbiology Galvez A. Abriouel H. Lopez R. L. Ben Omar. N. Bacteriocin 2007 120 51
Hsu KC, Cheng ML, Hwang JS.Hydrolysates from Tuna Cooking Juice as An Anti-Hypertensive Agent. Journal of Food and Drug Analysis 2007 15 169
Kim SE, Kim HH, Kim JY, Kang YI, Woo HJ, Lee HJ.Anticancer Activity of Hydrophobic Peptides from Soy Proteins. BioFactors 2000 12 151
Hsu KC, Lu GH, Jao CL. 2009Antioxidative Properties of Peptides Prepared from Tuna Cooking Juice Hydrolysates with Orientase (Bacillus subtilis). Food Research International 2009; 42 647
Fukui K. Tachibana N. Wanezaki S. Tsuzaki S. Takamatsu K. Yamamoto T. Hashimoto Y. Shimoda T. 2002Isoflavone-Free Soy Protein Prepared by Column Chromatography Reduces Plasma Cholesterol in Rats. Journal of Agricultural and Food Chemistry 2002; 50 5717
Comprehensive Reviews in Food Science and Food Safety Wang W. de Mejia E. G. A. New Frontier. in Soy. Bioactive Peptides. That May. Prevent-Related Age. Chronic Diseases. 2005 4 63
The Journal of Antibiotics Umezawa H. Aoyagi T. Ogawa K. Naganawa H. Hamada M. Takeuchi T. Diprotins A. Inhibitors B. of Dipeptidyl. Aminopeptidase I. V. Produced by. Bacteria 1984 37 422
Whey Proteins as Source of Dipeptidyl Dipeptidase IV (Dipeptidyl Peptidase-4) Inhibitors. Peptides Tulipano G. Sibilia V. Caroli A. M. Cocchi D. 2011 32 835
Novel Dipeptidyl Peptidase- Uchida M. Ohshiba Y. Orie Mogami. 4Inhibiting Peptide Derived from β-lactoglobulin. Journal of Pharmacological Sciences 2011
Pieter BJW. WO 2006Protein Hydrolysate Enriched in Peptides Inhibiting DPP-IV and Their Use. 2006.
Aart V. A. MJ Catharina-Wolbers Zeeland. Maria V. Gilst L. A. Hendrikus V. Nelissen W. Maria B. J. H. J. W. P. W. O. 2009Egg Protein Hydrolysates. 2009.
Protein Release from Gelatin Matrices. Advanced Drug Delivery Reviews Tabata Y. Ikada Y. 1998 31 287
Eastoe JE, Leach AA.Hemical Constitution of Gelatin. In The Science and Technology of Gelatin. Ward AG, Courts A, Eds. Academic Press: New York, NY; 1977 73 107
Li-Chan ECY, Huang SL, Jao CL, Ho KP, Hsu KC.Peptides Derived from Atlantic Salmon Skin Gelatin as Dipeptidyl-Peptidase IV Inhibitors. Journal of Agricultural and Food Chemistry 2012 60 973
Enzymic Hydrolysis of Food Proteins. Elsevier Applied Science Publisher: Alder-Nissen J. 1986
Journal of Agricultural and Food Chemistry Lo W. M. Y. Li-Chan E. C. Y. Angiotensin I. Converting Enzyme. Inhibitory Peptides. from in. vitro-Pancreatin Pepsin. Digestion of. Soy Protein. 2005 53 3369
Rapid Chromatographic Purification of Dipeptidyl Peptidase IV in Human Submaxiallry Gland. Journal of Chromatography A Kojima K. Ham T. Kato T. 1980 189 233